A detailed history of Mariner, LLC transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Mariner, LLC holds 26,585 shares of GALT stock, worth $74,969. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,585
Previous 26,476 0.41%
Holding current value
$74,969
Previous $59,000 23.73%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.04 - $2.86 $222 - $311
109 Added 0.41%
26,585 $73,000
Q2 2024

Aug 13, 2024

SELL
$2.13 - $4.2 $4,051 - $7,988
-1,902 Reduced 6.7%
26,476 $59,000
Q1 2024

May 15, 2024

BUY
$1.6 - $2.44 $28,000 - $42,700
17,500 Added 160.88%
28,378 $67,000
Q3 2023

Nov 13, 2023

BUY
$1.38 - $1.97 $107 - $153
78 Added 0.72%
10,878 $20,000
Q4 2022

Feb 14, 2023

SELL
$1.03 - $1.66 $584 - $941
-567 Reduced 4.99%
10,800 $12,000
Q3 2022

Nov 10, 2022

BUY
$1.31 - $2.48 $14,890 - $28,190
11,367 New
11,367 $19,000

Others Institutions Holding GALT

About GALECTIN THERAPEUTICS INC


  • Ticker GALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,426,000
  • Market Cap $168M
  • Description
  • Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...
More about GALT
Track This Portfolio

Track Mariner, LLC Portfolio

Follow Mariner, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.